Special Issue "Glioblastoma"

Guest Editor
Prof. Dr. Shi-Yuan Cheng
Department of Neurology, Northwestern Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center University of Northwestern Feinberg School of Medicine, 303 East Superior, Lurie 7-119, Chicago, IL 60026, USA
Website: http://www.biology.northwestern.edu/igp/faculty/cheng_s-y/index.html
E-Mail: shiyuan.cheng@northwestern.edu
Interests: oncogenic signaling; glioblastomas; breast cancers; cancer biology; molecular mechanisms of human cancer tumorigenesis, progression, invasion/metastasis and angiogenesis

Guest Editor
Prof. Dr. Frank Furnari
Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093-0660, USA
Website: http://pathology.ucsd.edu/faculty/furnari.htm?id=247
E-Mail: ffurnari@ucsd.edu
Phone: +1 858 534 7819
Fax: +1 858 534 7750
Interests: glioma; tumor heterogeneity; EGFR; PTEN; targeted therapeutics; receptor tyrosine kinases

Dear Colleagues,

Neoplasms of glial cells, especially astrocytes, comprise 40-50% of the tumors that arise in the central nervous system. The most aggressive and deadly of these neoplasms is glioblastoma multiforme (GBM). Despite rapidly increasing knowledge of the gliomagenic lesions that underlie these tumor phenotypes and decades of technological advances in neurosurgery, radiation therapy and clinical trials of conventional and novel therapies, little improvement in the median survival of 12-15 months has been achieved for GBM patients. Therefore, it is essential and urgent that we improve our current knowledge of the molecular and cellular mechanisms of GBM initiation, progression and resistance to therapy. This special issue will focus on new advances in the molecular and cellular aspects of the pathophysiology of GBM and novel therapeutic approaches to eradicate this deadly brain cancer.
We are looking forward to your contributions.

Prof. Dr. Shi-Yuan Cheng
Prof. Dr. Frank Furnari
Guest Editors

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

• molecular mechanisms of gliomagenesis and progression and therapy resistance
• glioma stem cells
• cancer metabolism
• therapies for malignant gliomas
• pathology/genomics
• miRNAs
• glioma tumor heterogeneity